AI Algorithm for Contact Dermatitis
What You Need to Know Before You Apply
What is the purpose of this trial?
The trial aims to improve remote patch allergy tests for individuals with contact dermatitis, a skin condition causing red, itchy rashes. The study will evaluate DermAI, an AI tool, to determine its accuracy in detecting allergic reactions by analyzing photos of patch test results taken at home. Participants will wear allergen patches on their arms, which both a doctor and the AI will assess for comparison. This trial suits those who have not recently used steroids and have no rashes or sunburns on their forearms. As an unphased trial, it offers participants the chance to contribute to innovative research that could enhance allergy testing methods.
Do I need to stop my current medications for the trial?
You may need to stop taking certain medications like topical or oral steroids two weeks before the patch testing. If you are on immunosuppression agents, you might not be eligible to participate.
What prior data suggests that this AI algorithm is safe for remote patch allergy testing?
Research has shown that DermAI is being used to improve allergy testing for skin reactions. This treatment helps identify allergic contact dermatitis, a condition that causes the skin to become red and itchy upon contact with certain substances.
Specific safety data for DermAI is not yet available, as the trial is in a phase called "Not Applicable." This phase suggests limited information on how well people tolerate it. However, since DermAI involves analyzing photos of skin reactions, it is less likely to cause side effects compared to treatments that require medication.
Overall, while solid evidence on the safety of DermAI is lacking, its method of operation suggests it might be well-tolerated.12345Why are researchers excited about this trial?
Unlike the standard of care for contact dermatitis, which typically involves topical steroids or antihistamines, DermAI offers a cutting-edge approach by using artificial intelligence to assess allergic reactions. Researchers are excited about this trial because DermAI could provide a faster and more precise diagnosis compared to traditional methods. This AI algorithm analyzes photographs of skin reactions, potentially allowing for quicker identification of allergens and more personalized treatment plans.
What evidence suggests that DermAI is effective for contact dermatitis?
Studies have shown that artificial intelligence (AI) can effectively diagnose contact dermatitis, a skin reaction. Research indicates that AI systems, such as DermAI, use advanced image recognition to identify skin allergies with approximately 85% accuracy. This means AI often correctly detects allergic reactions on the skin. In this trial, participants will have allergen patches applied, and the AI algorithm, DermAI, will analyze photos of the patch test sites to assist doctors in determining the presence of an allergy. This approach may simplify and enhance the reliability of allergy testing, particularly when conducted at home.24567
Who Is on the Research Team?
Matthew Hall, MD
Principal Investigator
Mayo Clinic
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants will have two allergen patches on their forearms for 48 hours, followed by a photograph for AI and human review
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- DermAI
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor